2018 Annual Report

Scientific
Leadership:
Catalyzing
Collaborations

Members from each AACR Project GENIE participating center and strategic partners gathered at the AACR offices in January for their Winter Summit.
The AACR identifies the challenges facing cancer scientists and clinicians; assembles leaders in various fields to address those challenges; and works with academic, industry, and government institutions to implement solutions that drive progress against cancer.

AACR Project GENIE: Powering Precision Medicine

As the founder of Project GENIE (Genomics Evidence Neoplasia Information Exchange), the AACR is working to deliver on the promise of precision medicine. Built upon data sharing between the world’s leading cancer centers, AACR Project GENIE is an international cancer registry that aggregates clinical-grade tumor sequencing data with limited clinical data to build virtual cohorts of patients on whom detailed outcomes data can be retrieved. By offering insights into the relationships between genotype and patient outcome, the project powers translational and clinical research—facilitating the development of new therapies, informing the design of better clinical trials, and improving clinical decision-making for the benefit of all cancer patients.

The increasing momentum of AACR Project GENIE over the past year was reflected in the number of institutions expressing interest in joining the consortium, which more than doubled in size in 2018 as 11 new participating organizations joined the eight founding participants (right). The expansion of the consortium was accompanied by an expansion of the data set, as releases in January and July increased the number of sequenced tumors by more than 50 percent. AACR Project GENIE is now one of the largest fully public cancer genomic datasets, with more than 48,000 de-identified genomic records covering more than 80 cancer types.

In February 2018—one year after the release of the first data set—members of the consortium published a paper in the journal JCO Clinical Cancer Informatics that detailed the genesis of the project and shared the perspectives of the founding institutions. The paper, which was intended to share best practices and serve as a guide for other organizations who wish to develop their own genomic data-sharing consortia, was among the most read articles in the journal in July 2018.

AACR Project GENIE is also supporting the “2020 by 2020” Presidential initiative and collaboration. Announced in March 2018, this initiative from AACR President (2017-2018) Michael A. Caligiuri, MD, FAACR, will perform genomic sequencing of both tumor and normal tissue from 2,020 consented African-American cancer patients by the year 2020 and aggregate this valuable information with clinical data from these patients. The genomic data will be made publicly available through the Project GENIE registry and the Oncology Research Information Exchange Network (ORIEN) to benefit researchers who are studying cancer and cancer outcomes in African-American populations with the goal of addressing this serious public health challenge.



AACR Think Tank on Cancer Health Disparities

One of the major goals of Dr. Caligiuri’s presidential year was to confront and overcome the challenges of cancer health disparities. A major step toward reaching this ambitious goal was the formation of an AACR Think Tank on Cancer Health Disparities. Under the leadership of chair John D. Carpten, PhD, and cochairs Marcia R. Cruz-Correa, MD, PhD, Brian M. Rivers, PhD, MPH, and Sanya A. Springfield, PhD, the think tank met in Washington, DC, in October to address three critical elements of the cancer disparities problem: 1) increasing participation of underrepresented/minority patients in clinical trials; 2) developing key resources to accelerate cancer health disparities research; and 3) training the cancer health disparities workforce to meet emerging needs. Participants in the think tank meeting included James W. Lillard, PhD, MBA, associate dean for Research at Morehouse School of Medicine and principal investigator of the 2020 by 2020 Initiative; and 2018-2019 AACR President Elizabeth M. Jaffee, MD, FAACR.

AACR Project GENIE
Founding Consortium Participants
Dana-Farber Cancer Institute, Boston, Massachusetts
Gustave Roussy Cancer Campus, Paris-Villejuif, France
The Netherlands Cancer Institute, Amsterdam, on behalf of the Center for Personalized Cancer Treatment, Utrecht, The Netherlands
Memorial Sloan Kettering Cancer Center, New York, New York
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
The University of Texas MD Anderson Cancer Center, Houston, Texas
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
New Consortium Participants
Children’s Hospital of Philadelphia Cancer Center, Philadelphia, Pennsylvania
Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, England
Duke University (Duke Cancer Institute), Durham, North Carolina
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York
Swedish Cancer Institute, Seattle, Washington
Providence Cancer Institute, Portland, Oregon
Wake Forest University Health Sciences, Winston-Salem, North Carolina
The University of Chicago Comprehensive Cancer Center, Chicago, Illinois
University of California-San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Vall d’Hebron Institute of Oncology, Barcelona, Spain
Yale Cancer Center, New Haven, Connecticut

AACR Pathology Task Force

Recognizing the vital role that pathologists play in delivering timely and accurate diagnoses to support the most effective treatment decisions, the AACR convened a Pathology Task Force in December to identify ways the association can better serve the field. Chaired by Massimo F. Loda, MD, the task force gathered thought leaders and stakeholders in academia, industry, and government to survey the challenges facing the field of cancer pathology and to develop innovative solutions to those challenges for the benefit of cancer patients.

Cancer Prevention Summit: White Paper on the Future of Cancer Prevention

In February 2016, the AACR convened a three-day Cancer Prevention Summit, bringing together nearly 70 scientists, clinicians, patient advocates, and funders to set a course for future efforts in cancer prevention research. In December, under the leadership of chairs Ernest T. Hawk, MD, MPH, and Scott M. Lippman, MD, the summit participants published a white paper in the AACR journal Cancer Prevention Research titled “Shaping the Future of Cancer Prevention—A Roadmap for Advancing Science and Public Health.”

Scientific
Working
Groups

Johanna A. Joyce, PhD, delivers her presentation on "Microenvironmental regulation of cancer metastasis and therapeutic efficacy" during the Cancer Immunology (CIMM)/Tumor Microenvironment (TME) Working Groups Joint Scientific Session, held during the AACR Annual Meeting 2018.
AACR scientific working groups facilitate progress against cancer through collaboration. By building communities around areas of scientific interest, the AACR aligns the efforts of its members to address the most challenging questions in cancer research.

Pediatric Cancer Working Group (PCWG): Facilitating International Cooperation and Coordination

While the AACR’s PCWG works to address the scientific challenges facing the pediatric cancer field, the group also addresses the logistical challenges that hinder progress for children with cancer. One such challenge was a lack of coordination between two of the largest pediatric cancer drug development consortia, the NCI Pediatric Preclinical Testing Consortium (PPTC) in the United States and the Innovative Therapies for Children with Cancer (ITCC) Pediatric Preclinical Proof-of-Concept Program (P4) in Europe. These consortia bring together scientists, clinicians, regulators, and patients to develop novel pediatric cancer therapies. To maximize the impact of critical research resources, it is imperative that the organizations avoid duplication of effort. Leveraging its international membership and the AACR’s reputation as an honest broker, PCWG began acting as an intermediary between these consortia in 2018, aligning their efforts to accelerate the pace of progress against pediatric cancer. At the AACR Annual Meeting 2018, the PCWG brought the consortia together for a special session to discuss the preclinical models they have developed, the therapeutic agents they are currently testing, and opportunities to collaborate for the benefit of pediatric cancer patients worldwide.

RADIATION SCIENCE AND MEDICINE (RSM): NEW CHALLENGES, NEW COLLABORATIONS

The mission of the AACR’s Radiation Science and Medicine Working Group (RSM) is to foster the application of radiation science and medicine to understand and treat cancer malignancies. In June, RSM advanced that mission by hosting a think tank on Illuminating Technological Advances and Challenges in Precision Radiotherapies. Supported in part by Bayer Pharmaceuticals, the think tank convened more than 30 experts in all areas of radiation science—including radiobiology, medical physics, and nuclear medicine—to highlight current and emerging radiotherapy technologies, address the critical needs of the field, and discuss the most effective approaches to improving patient care.

Preventing and curing cancer through collaboration is one of the pillars of the AACR mission, and RSM joined forces with two other scientific organizations in 2018 to advance that mission:

  • A major concern among clinicians is the lack of cancer drugs intended specifically for use with radiation therapy. In February, the AACR partnered with the Food and Drug Administration (FDA) and the American Society for Radiation Oncology (ASTRO) to host a regulatory science and policy workshop on Clinical Development of Drug-Radiotherapy Combinations. The workshop brought together regulators with academic and industry scientists to identify the drug development challenges and to develop a strategy to overcome them.
  • In March, the AACR worked with the Radiation Research Society (RRS) to cohost a workshop on Targeting Cancer Metabolism to Improve Radiotherapy that explored the critical interface between tumor metabolism and radiotherapy response. Chaired by Julie Schwarz, MD, PhD, Douglas Spitz, PhD, and David Gius, MD, PhD, the workshop gathered radiobiologists, radiologists, and radiation oncologists to share the program with basic scientists focused on tumor metabolism.
  • The AACR and ASTRO collaborated again to host a workshop on Targeting the Tumor Microenvironment in Radiation Oncology in July. The meeting—which was chaired by Wendy Woodward, MD, PhD, and Amato Giaccia, PhD—addressed critical topics such as tumor stromal effects on radiosensitivity and radioresistance, immune response to radiotherapy, and the effect of metabolism on the tumor microenvironment and the efficacy of radiotherapy efficacy.

MOLECULAR EPIDEMIOLOGY WORKING GROUP (MEG): ADDRESSING CANCER HEALTH DISPARITIES

At the AACR Annual Meeting 2018, MEG worked with the AACR Minorities in Cancer Research (MICR) Council to present an inaugural joint symposium on “Aggressive Cancer Phenotypes in Racial/Ethnic Minority Populations: Opportunities and Challenges.” Moderated by MICR Council Chair-Elect Laura Fejerman, PhD, and MEG Steering Committee Chair Melissa L. Bondy, PhD, the session addressed the greater susceptibility of different minority populations to aggressive forms of cancer.

SCIENCE EDUCATION, CAREER DEVELOPMENT, AND CONTINUING MEDICAL EDUCATION

AACR CEO Margaret Foti, PhD, MD (hc) congratulates the inaugural recipients of the Margaret Foti Foundation Undergraduate Prizes for Cancer Research.
Continued progress against cancer requires a robust workforce consisting of dedicated scientists and clinicians at all career levels. Through its science education and professional development programs, the AACR inspires and prepares young people to pursue careers in cancer science and supports these emerging investigators at all stages of their career paths.

Student Members: Fostering the Next Generation of Cancer Scientists

The AACR continued its long-standing support of students interested in careers in science at the Annual Meeting 2018. At the annual Special Program for High School Students, nearly 300 students were welcomed to Chicago to participate in interactive lectures on cancer development and prevention and to tour the exhibits and poster sessions. In addition, 11 high school students presented their own research and received feedback on their projects from AACR scientist mentors.

More than 200 undergraduate students also attended the AACR Annual Meeting to participate in the Thirteenth Annual Undergraduate Student Caucus and Poster Competition. The poster competition featured presentations from more than 115 students, whose research projects were evaluated by leading AACR members. Presenters of the most highly-rated posters were recipients of the inaugural Margaret Foti Foundation Undergraduate Prizes for Cancer Research. Funded by AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), the prizes encourage college students who are interested in science to pursue careers in cancer research.

Supporting Postdoctoral Fellows

The National Postdoctoral Association (NPA) is a nonprofit member organization that works to enhance the quality of the postdoctoral experience in the United States. As a sustaining member of the NPA, the AACR expresses its appreciation for the vital contributions of postdoctoral scholars to the cancer research enterprise and demonstrates its commitment to expanding the opportunities available to postdocs through education and training.

In September, the AACR participated in National Postdoc Appreciation Week activities by hosting two Cancer Careers Clinics at Drexel University and the University of Pennsylvania. AACR staff provided participants with advice on navigating the interview and negotiation processes, managing the transition to a full-time position, and submitting successful publications and grant applications.



Continuing Medical Education

As an ACCME-accredited provider, the AACR offered CME credit at 20 different meetings in 2018, including ten focused special conferences, three joint conferences, two educational workshops, two joint providership activities, and the AACR Annual Meeting. AACR journals provided another educational resource, offering credit to investigators for reviewing manuscripts. A total of 3,611 researchers and clinicians claimed CME credit from the AACR in 2018, taking advantage of opportunities to maintain their professional competence and incorporate new knowledge into their practices.

Mya Roberson, MSPH
AACR Associate Member
Past AACR Undergraduate Scholar

Meetings and Educational Workshops

Scientific committee chair Ari M. Melnick, MD, addresses attendees of the AACR International Meeting on Advances in Malignant Lymphoma, held in Boston in June.
AACR meetings and educational workshops bring the latest advances in cancer science to researchers around the world. The AACR collaborated with 16 scientific organizations to convene 32 meetings in ten countries in 2018, the most in its history. The organization also recognized a significant milestone in 2018, which marked the 30th year of its special conferences program. To celebrate 30 years of scientific excellence, the AACR invited Nobel Laureate Phillip A. Sharp, PhD, FAACR—the chairperson of the first special conference in 1988—to chair an anniversary conference on “Convergence: Artificial Intelligence, Big Data, and Prediction in Cancer.”

While acknowledging the rich history of its special conference series, the AACR also advanced its meetings program into new scientific areas in 2018. One of the scientific priorities identified by the AACR Board of Directors in its Vision 2020 Strategic Plan was an expanded focus on hematological malignancies. To realize this critical vision, the AACR partnered with the organizers of the International Conference on Malignant Lymphoma (ICML)—held semiannually in Lugano, Switzerland, since 1981—to bring a version of this premier forum for malignant lymphoma research to the United States. In June, the inaugural AACR International Meeting on “Advances in Malignant Lymphoma” was held in Boston. Under the leadership of Scientific Committee chair Ari M. Melnick, MD, the meeting employed a unique, discussion-driven format to discuss recent advances and emerging areas of lymphoma research and their potential for transforming patient care. Going forward, the meeting will be held annually and will alternate between the United States and Switzerland, ensuring that hematological malignancies remain a critical priority for the cancer research community.

2018 WORKSHOPS

Meeting or Workshop Held outside U.S.
  • ACCELERATING ANTICANCER AGENT DEVELOPMENT AND VALIDATION WORKSHOP
    May 2-4; Bethesda, Maryland
    Executive Committee: H. Kim Lyerly, MD, Richard Pazdur, MD, Gregory Reaman, MD, and Mary Scroggins, MA
  • ECCO-AACR-EORTC-ESMO WORKSHOP ON METHODS IN CLINICAL CANCER RESEARCH
    June 16-22; Zeist, The Netherlands
    Codirectors: Stefan Sleijfer, MD, PhD, Lee M. Ellis, MD, Corneel Coens, MSc, and Emiliano Calvo, MD, PhD
  • INTEGRATIVE MOLECULAR EPIDEMIOLOGY WORKSHOP: BRIDGING CANCER BIOLOGY AND PRECISION MEDICINE
    July 9-13; Boston, Massachusetts
    Director: Thomas A. Sellers, PhD, MPH
    Codirectors: Peter Kraft, PhD, and Lorelei A. Mucci, ScD, MPH
  • MOLECULAR BIOLOGY IN CLINICAL ONCOLOGY WORKSHOP
    July 22-29; Snowmass Village, Colorado
    Director: Ross L. Levine, MD
    Codirectors: Mark W. Geraci, MD, Christine M. Lovly, MD, PhD, and Jean Y. Tang, MD, PhD
  • AACR/ASCO METHODS IN CLINICAL CANCER RESEARCH WORKSHOP
    July 28-August 3; Vail, Colorado
    Codirectors: Patricia M. LoRusso, DO, Jyoti D. Patel, MD, and Meredith M. Regan, ScD
  • ACORD—AUSTRALIA & ASIA PACIFIC ONCOLOGY RESEARCH DEVELOPMENT WORKSHOP
    September 9-14; Magenta Shores NSW Central Coast, Sydney, Australia
    Organizing Committee: Zeba Aziz, MBBS, Gary M. Clark, PhD, Reena Nair, MD, Katrin Sjoquist, MBBS, Martin Stockler, MBBS, and Nirav P. Trivedi, MS, MCh
  • TRANSLATIONAL CANCER RESEARCH FOR BASIC SCIENTISTS WORKSHOP
    November 4-9; Boston, Massachusetts
    Codirectors: George D. Demetri, MD, Susan Band Horwitz, PhD, FAACR, and Pasi A. Jänne, MD, PhD

Nmazuo W. Ozuah, MD
AACR/ASCO Methods in Clinical Cancer Research Workshop Participant

2018 SCIENTIFIC MEETINGS

  • FIFTH AACR-IASLC INTERNATIONAL JOINT CONFERENCE: LUNG CANCER TRANSLATIONAL SCIENCE FROM THE BENCH TO THE CLINIC
    January 8-11; San Diego, California
    Chairs: Charles M. Rudin, MD, PhD, and Charles Swanton, PhD
    Cochairs: Tony S.K. Mok, MD, Lecia V. Sequist, MD, MPH, and Monte M. Winslow, PhD
  • OBESITY AND CANCER: MECHANISMS UNDERLYING ETIOLOGY AND OUTCOMES
    January 27-30; Austin, Texas
    Cochairs: Lewis C. Cantley, PhD, FAACR, Michael N. Pollak, MD, and Elizabeth A. Platz, ScD, MPH
  • IMMUNOBIOLOGY OF PRIMARY AND METASTATIC CNS CANCER: MULTIDISCIPLINARY SCIENCE TO ADVANCE CANCER IMMUNOTHERAPY
    Presented in association with the AACR Cancer Immunology Working Group
    February 12-15; San Diego, California
    Cochairs: Hideho Okada, MD, PhD, Robyn S. Klein, MD, PhD, Ignacio Melero, MD, PhD, and Patricia S. Steeg, PhD
  • THIRD AACR-SNMMI JOINT CONFERENCE ON STATE-OF-THE-ART MOLECULAR IMAGING IN CANCER BIOLOGY AND THERAPY
    February 14-17; San Diego, California
    Cochairs: Todd E. Peterson, PhD, and David R. Piwnica-Worms, MD, PhD
  • TARGETING DNA METHYLATION AND CHROMATIN FOR CANCER THERAPY
    March 1-4; Atlanta, Georgia
    Cochairs: Stephen B. Baylin, MD, FAACR, Margaret A. Goodell, PhD, and Peter A. Jones, PhD, DSc, FAACR
  • AACR ANNUAL MEETING 2018
    April 14-18; Chicago, Illinois
    Program Committee Chair: Elaine R. Mardis,  PhD
  • CANCER DORMANCY AND RESIDUAL DISEASE
    June 19-22; Montreal, Quebec, Canada
    Cochairs: Julio A. Aguirre–Ghiso, PhD, Ann F. Chambers, PhD, Cyrus M. Ghajar, PhD, Christoph A. Klein, MD, PhD, and Dorothy A. Sipkins, MD, PhD
  • INAUGURAL AACR INTERNATIONAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA: MAXIMIZING THE BASIC-TRANSLATIONAL INTERFACE FOR CLINICAL APPLICATION
    In cooperation with the International Conference on Malignant Lymphoma (ICML)
    June 22-26; Boston, Massachusetts
    Chair: Ari M. Melnick, MD
    Cochairs: Francesco Bertoni, MD, Renier J. Brentjens, MD, PhD, Bertrand Nadel, PhD, Lisa G. Roth, MD, Louis M. Staudt, MD, PhD, Christian Steidl, MD, Karin Tarte, PharmD, PhD, Thomas E. Witzig, MD, and Wei-Li Zhao, MD
  • SIXTH JCA-AACR SPECIAL JOINT CONFERENCE ON THE LATEST ADVANCES IN LUNG CANCER RESEARCH: FROM BASIC SCIENCE TO THERAPEUTICS
    July 10-12; Kyoto, Japan
    Organizing Committee (JCA): Hiroyuki Mano, MD, PhD, Seiji Yano, MD, PhD, and Hiroyoshi Nishikawa, MD, PhD
    Organizing Committee (AACR): Alice T. Shaw, MD, PhD, Roy S. Herbst, MD, PhD, and Charles M. Rudin, MD, PhD
  • 12TH BIENNIAL OVARIAN CANCER RESEARCH SYMPOSIUM
    Presented by the Rivkin Center for Ovarian Cancer and the AACR
    September 13-15; Seattle, Washington
    Cochairs: Frances R. Balkwill, PhD, Mary L. (Nora) Disis, MD, Pamela S. Ohashi, PhD, and Elizabeth M. Swisher, MD
  • PANCREATIC CANCER: ADVANCES IN SCIENCE AND CLINICAL CARE
    September 21-24; Boston, Massachusetts
    Cochairs: Ronald M. Evans, PhD, FAACR, Manuel Hidalgo, MD, PhD, Steven D. Leach, MD, Gloria M. Petersen, PhD, and Brian M. Wolpin, MD, MPH
  • INTESTINAL STEM CELLS AND COLON CANCER: BIOLOGY TO THERAPY
    September 27-30; Washington, DC
    Cochairs: Anil K. Rustgi, MD, Johanna C. Bendell, MD, Hans Clevers, MD, PhD, FAACR, Christina Curtis, PhD, and Owen Sansom, PhD
  • SECOND AACR INTERNATIONAL CONFERENCE: TRANSLATIONAL CANCER MEDICINE, CANCER DISCOVERIES FOR CLINICAL APPLICATION
    Held in cooperation with the Latin American Cooperative Oncology Group (LACOG)
    September 27-29; São Paulo, Brazil
    Cochairs: Carlos L. Arteaga, MD, FAACR, Carlos Gil Ferreira, MD, PhD, and Gabriel A. Rabinovich, PhD
  • METABOLISM AND CANCER
    September 28-October 1; New York, New York
    Cochairs: Ralph J. DeBerardinis, MD, PhD, Tak W. Mak, PhD, FAACR, Joshua D. Rabinowitz, MD, PhD, and M. Celeste Simon, PhD
  • FOURTH CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE: TRANSLATING SCIENCE INTO SURVIVAL
    September 30-October 3; New York, New York
    Cochairs: Nina Bhardwaj, MD, PhD, Christoph Huber, MD, Elizabeth M. Jaffee, MD, FAACR, and Guido Kroemer, MD, PhD
  • EACR-AACR-ISCR CONFERENCE: THE CUTTING EDGE OF CONTEMPORARY CANCER RESEARCH
    October 9-11; Jerusalem, Israel
    Cochairs: Richard M. Marais, PhD, Eli Pikarsky, MD, PhD, and Robert A. Weinberg, PhD, FAACR
  • 30TH ANNIVERSARY AACR SPECIAL CONFERENCE CONVERGENCE: ARTIFICIAL INTELLIGENCE, BIG DATA, AND PREDICTION IN CANCER
    October 14-17; Newport, Rhode Island
    Cochairs: Phillip A. Sharp, PhD, FAACR, and William C. Hahn, MD, PhD
    Program Committee: Judy E. Garber, MD, MPH, FAACR, Richard D. Klausner, MD, FAACR, Aviv Regev, PhD, and Charles L. Sawyers, MD, FAACR
  • 11TH AACR CONFERENCE ON THE SCIENCE OF CANCER HEALTH DISPARITIES IN RACIAL/ETHNIC MINORITIES AND THE MEDICALLY UNDERSERVED
    In association with the AACR Minorities in Cancer Research Council
    November 2-5; New Orleans, Louisiana
    Cochairs: Ivis Febus-Sampayo, Laura Fejerman, PhD, Scarlett Lin Gomez, MPH, PhD, Augusto C. Ochoa, MD, and Brian M. Rivers, PhD
  • EORTC-NCI-AACR MOLECULAR TARGETS AND CANCER THERAPEUTICS SYMPOSIUM
    November 13-16; Dublin, Ireland
    Cochairs: Charles Swanton, MD, PhD, James L. Gulley, MD, PhD, and Antoni Ribas, MD, PhD
  • AACR-KCA JOINT CONFERENCE ON PRECISION MEDICINE IN SOLID TUMORS
    November 15-17; Seoul, Korea
    Cochairs: Tae-You Kim, MD, PhD, and Charles L. Sawyers, MD, FAACR
  • TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
    November 27-30; Miami Beach, Florida
    Cochairs: James P. Allison, PhD, FAACR, Lisa M. Coussens, PhD, Ira Mellman, PhD, and Drew M. Pardoll, MD, PhD
  • INNOVATION AND BIOMARKERS IN CANCER DRUG DEVELOPMENT: A JOINT MEETING PRESENTED BY EORTC, NCI, EMA, AND AACR
    November 29-30; Brussels, Belgium
    Chairs: Denis A. Lacombe, MD, MSc, and Roberto Salgado, MD, PhD
    Cochairs: Jonas C. S. Bergh, MD, Michael A. Caligiuri, MD, FAACR, Lyndsay N. Harris, MD, Tracy G. Lively, PhD, Francesco Pignatti, MD, and Victor E. Velculescu, MD, PhD
  • TARGETING PI3K/MTOR SIGNALING
    November 30-December 3; Boston, Massachusetts
    Cochairs: Lewis C. Cantley, PhD, FAACR, David M. Sabatini, MD, PhD, and Jean J. Zhao, PhD
  • SAN ANTONIO BREAST CANCER SYMPOSIUM
    December 4-8; San Antonio, Texas
    Cochairs: Carlos L. Arteaga, MD, FAACR, Virginia G. Kaklamani, MD, and C. Kent Osborne, MD
  • TARGETING RAS-DRIVEN CANCERS
    December 9-12; San Diego, California
    Cochairs: Frank McCormick, PhD, FAACR, Gideon Bollag, PhD, Karen M. Cichowski, PhD, and Shiva Malek, PhD